Marshall Edwards, Inc. to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
October 30 2006 - 9:09AM
PR Newswire (US)
NEW YORK, Oct. 30 /PRNewswire-FirstCall/ -- Novogen Limited's
subsidiary, Marshall Edwards, Inc. (NASDAQ:MSHL) has announced that
the Company will present at the Rodman & Renshaw 8th Annual
Healthcare Conference at the New York Palace Hotel on Wednesday
November 8, 2006 at 12:45 pm. About Marshall Edwards, Inc. Marshall
Edwards, Inc. has licensed rights from Novogen Limited
(NASDAQ:NVGN) to bring three oncology drugs -- phenoxodiol, NV-196
and NV-143 -- to market globally. Marshall Edwards, Inc. is
majority owned by Novogen, an Australian biotechnology company that
is specializing in the development of therapeutics based on
regulation of the sphingomyelin pathway. Novogen, based in Sydney,
Australia, is developing a range of therapeutics across the fields
of oncology, cardiovascular disease and inflammatory diseases. More
information on phenoxodiol and on the Novogen group of companies
can be found at http://www.marshalledwardsinc.com/ and
http://www.novogen.com/. Under U.S. law, a new drug cannot be
marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
arty patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents
and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to
obtain any additional required financing; technological changes;
government regulation; changes in industry practice; and one-time
events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these
forward-looking statements. DATASOURCE: Marshall Edwards, Inc.
CONTACT: Mr. Christopher Naughton, Managing Director of Novogen
Limited, +61 (02) 9878 0088; or David Sheon, +1-202 518-6321, for
Marshall Edwards, Inc. Web site: http://www.marshalledwardsinc.com/
http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024